Menu

CME Corner

This activity has expired. CME/CE credit is no longer available and the following content may not be available or may not be up-to-date. For a list of current activities that offer CME/CE credit, click here.

Program Detail

Release Date: August-15-08
Credit Expiration Date: August-15-09

Faculty

Barry J. Make, MD
Professor of Medicine
University of Colorado School of Medicine
Co-Director, COPD Program
Director, Pulmonary Rehabilitation and Respiratory Care
National Jewish Medical and Research Center
Denver, Colorado

Robert A. Wise, MD
Professor of Medicine
Johns Hopkins University School of Medicine
Baltimore, Maryland

Credit Hours

1 hour

Medium

Interactive Virtual Clinic

Program Description

As the fourth leading cause of death in the United States, chronic obstructive pulmonary disease (COPD) remains a major public health issue. Although COPD has no cure, its progression can be slowed and its symptoms managed through appropriate treatment.

In recent years, COPD research output has increased, contributing a new understanding of the epidemiology and pathophysiology of the condition. Many effective treatments are now available. COPD management guidelines have been issued by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) and American Thoracic Society / European Respiratory Society. Treatment for COPD can include inhaled pharmacologic therapy with short- or long-acting bronchodilators, inhaled corticosteroids, pulmonary rehabilitation, disease management, and supplemental oxygen.

Clinicians caring for patients with COPD need to be aware of the emerging concepts in the field, and to become familiar with recent and ongoing studies evaluating the safety and efficacy of current and emerging therapies. The appropriate treatment regimen can provide symptomatic benefit to patients with COPD and increase their quality of life and daily functioning.

Program Developer/Facilitator


.

Target Audience

Pulmonologists and other physicians with an interest in the management of COPD.

Learning Objectives

Upon completion of this educational activity, the participant should be able to:

  1. Describe emerging concepts in COPD epidemiology and pathophysiology
  2. Describe COPD exacerbations and ways to reduce their frequency using new agents and evidence-based therapies
  3. Manage comorbidities and other extrapulmonary effects that may contribute to the severity of COPD in individual patients

Disclosures

It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by AKH prior to accreditation of the activity.

Barry J. Make, MD, discloses that he has served as a consultant for AstraZeneca and Chiesi, and served on speakers’ bureaus for Boehringer Ingelheim Pharmaceuticals, Inc., GlaxoSmithKline, and Pfizer Inc. He has received research support from Boehringer Ingelheim Pharmaceuticals, Inc., GlaxoSmithKline, and Pfizer Inc., and served on the advisory boards of Boehringer Ingelheim Pharmaceuticals, Inc., Dey, Forest Laboratories, Inc., GlaxoSmithKline, Pfizer Inc., Respironics and Schering Plough Corporation.

Robert A. Wise, MD, discloses that he has served as a consultant for Abbott Laboratories, AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., GlaxoSmithKline, Pfizer Inc., Eli Lilly and Company, Otsuka America Pharmaceutical Inc., Novartis Pharmaceuticals Corporation, and Schering-Plough Corporation. He has also received research support from Boehringer Ingelheim Pharmaceuticals, Inc., Forest Laboratories, Inc., GlaxoSmithKline, and Merck and Co., Inc.

This educational activity contains discussion of published and/or investigational uses of fluticasone/salmeterol (500/50) and budesonide/formoterol for the treatment of COPD that have not been approved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Credit Statements

This activity has been planned and implemented in accordance with the Essential Areas and polices of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of AKH Inc. and Medical Communications Media, Incorporated. AKH Inc. is accredited by the ACCME to provide continuing medical education for physicians.

AKH Inc. designates this educational activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

This activity should take approximately 60 minutes to complete. Credit will be awarded for scoring 70% or better on the post-test. One retake is permitted.

Commercial Support Statements

.

Certificate Fee

$0.00

Disclaimer

None of the contents of this activity may be reproduced in any form without prior written permission of the publisher. The opinions expressed in this activity are those of the speakers and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, AKH Inc., or AstraZeneca. Any medications, or other diagnostic or treatment procedures discussed by the program speakers should not be utilized by clinicians without evaluation of their patients’ conditions and of possible contraindications or risks, and without a review of any applicable manufacturer’s product information and comparison with the recommendations of other authorities.

By clicking START PROGRAM I acknowledge that I have read the CME/CE information above.

Main Menu
EDITOR'S PICKS